NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Incidence of infections that cause gastrointestinal symptoms on the rise again In 2021, the incidence of enteric infections – which mainly cause gastrointestinal symptoms – was higher than in 2020, but still lower than before the coronavirus pandemic. This is the outcome of a study into enteric infections and pathogens transmitted from animals to humans.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
RIVM calls for increased involvement of scientific community in solving plastic crisis Industry and policymakers are not availing themselves enough of the available scientific knowledge when it comes to smarter ways of dealing with plastics.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).
Estimated costs of foodborne infections 140 million euros lower in 2020 In 2020, the estimated costs of foodborne infections in the Netherlands were 140 million euros lower than in the preceding year. This corresponds to a 30% decrease. ANP